Supplementary Information

Title: Factor XIa Inhibitors for Secondary Prevention After Ischemic Stroke or Transient Ischemic Attack: A Meta-Analysis of Randomized Clinical Trials

Authors: Toshiyuki Kawashima, Christian A. Bohoun, Takehiro Uda

Affiliation: Department of Neurosurgery, Osaka Metropolitan University Hospital, Osaka, Japan.

Table 1. Characteristics of Included Randomized Controlled Trials of Factor XIa Inhibitors for Secondary Stroke Prevention

Study	Trial phase	Randomization ratio	Intervention and dose	Background antiplatelet therapy	Index event distribution	Analysis population	Treatment duration	Follow-up duration	Funding source
AXIOMATIC-SSP	Phase 2, dose-finding	1:1:1:1:1:2	Milvexian 25 mg once daily; 25 mg twice daily; 50 mg twice daily; 100 mg twice daily; or 200 mg twice daily vs placebo	Clopidogrel 75 mg daily for 21 days plus aspirin 100 mg daily for 90 days	Ischemic stroke: 1,790/2,366 (75.7%); high-risk TIA: 576/2,366 (24.3%)	Efficacy: participants allocated to treatment who completed follow-up MRI; safety: participants receiving at least one dose	90 days	90 days; vital status known for 97% at trial end	Bristol Myers Squibb and Janssen Research & Development
PACIFIC-Stroke	Phase 2b, dose-finding	1:1:1:1	Asundexian 10 mg, 20 mg, or 50 mg once daily vs placebo	Usual antiplatelet therapy selected locally; stratified by planned single versus dual antiplatelet therapy. Dual therapy was used in 43% of participants.	All participants had acute non-cardioembolic ischemic stroke; no TIA participants	Efficacy: all randomized participants; safety: participants receiving at least one dose	26–52 weeks	At least 26 weeks, up to 52 weeks; final MRI at 26 weeks	Bayer AG
OCEANIC-STROKE	Phase 3, event-driven	1:1	Asundexian 50 mg once daily vs placebo	Planned dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor, or planned single antiplatelet therapy; randomization stratified by intended regimen	Noncardioembolic ischemic stroke or high-risk TIA; exact proportions were not identified in the supplied text	Randomized population appears to be the primary analysis population; all patients were followed to trial completion regardless of study-drug status	Continued until trial completion; no fixed duration stated in the extracted text	Median 574 days, based on your current table	Bayer

Figure S1. Flowchart of Study Screening




Figure S2. Risk of Bias for the Enrolled Study with All Outcomes




Figure S3. Publication Bias for Ischemic Stroke




Figure S4. Publication Bias for Transient Ischemic Attack




Figure S5. Publication Bias for All-Cause Death




Figure S6. Publication Bias for Major Bleeding

